InSyBio is thrilled to announce the release of InSyBio Suite Version 3.4, with a major upgrade to the InSyBio Interact tool, an advanced environment for protein analysis, protein–protein interaction (PPI) information retrieval, functional annotation, and biological network creation.
InSyBio Interact v3.4 features improved PPI search capabilities supported by a comprehensive database of more than 2 million positive and negative interactions. The tool includes the fully resolved interactome of all taste receptors (816,518 potential interactions), mined as part of the VIRTUOUS Horizon Europe 2020 project (https://www.virtuoush2020.com/), as well as the complete interactome of bone degeneration–related proteins (877,501 potential interactions), characterized through the REGENERATION Horizon Europe 2020 project (https://regenerationhorizon.eu/), along with many additional mined interactions. These interactions were predicted using an advanced ML methodology based on InSyBio’s proprietary Evolutionary Optimization Algorithm for developing classification and regression models that estimate both PPI class and interaction affinity. Users can filter interactions by adjusting their preferred classification confidence and affinity thresholds, and each interaction is accompanied by 75 computationally derived features and cross-references to major PPI databases, enabling comprehensive interpretation and high-confidence filtering.
The new version also introduces an enhanced protein analysis module that allows users to retrieve rich structural, sequential, and functional information for any protein, including detailed GO terms, miRNA regulators, and protein interaction partners enriched with a wide range of structural, co-expression, and physicochemical features. These data can be instantly visualized through an upgraded, interactive network interface that supports multiple layouts and downloadable graph formats.
The release features a new generation of computationally predicted protein complexes, developed using an updated EEMC algorithm. These complexes are presented with functional annotations and direct links to visualization, enabling quick identification of biologically meaningful modules.
Functional exploration is further strengthened with a redesigned GO term interface, allowing researchers to examine proteins and complexes associated with any biological process, molecular function, or cellular component. A rebuilt dataset creation module enables users to generate balanced or custom PPI datasets, including optional normalization and iRefIndex-verified interactions, with an option to store them directly within the InSyBio Data Store.
For systems-level analysis, users can now create full biological networks from lists of biomarkers or protein identifiers. These networks can be interactively visualized, explored, and exported in multiple formats, with full compatibility with InSyBio BioNets for further analysis.
With Version 3.4, InSyBio strengthens the field of PPI analysis, protein exploration, and network biology. The updated InSyBio Interact environment brings together high-accuracy PPI prediction, an expanded protein search module, and complex identification. By utilizing InSyBio’s advanced ML capabilities, researchers can move smoothly from examining a single protein’s characteristics to exploring its interaction partners, regulatory molecules, functional roles, and placement within broader biological systems.
InSyBio CEO Labros Digonis stated: “Protein interaction analysis remains fragmented and technically demanding. With Version 3.4, we integrate PPI prediction, protein analysis, complex detection, and interactive network biology into a single, user-friendly platform. Our goal is to empower researchers to extract actionable insights from complex biological data without requiring programming or specialized bioinformatics expertise.”
A detailed description of all new features is available in the InSyBio Interact User Manual v3.4: ( InSyBio Interact – InSyBio )
Researchers may request a free one-month trial of InSyBio Suite, including all new functionalities, by clicking on the following link: (https://suite.insybio.com/)
About InSyBio. InSyBio is an international pioneer biotechnology company revolutionizing the medical field through targeted biomarker discovery, highly accurate predictive analytics, and the development of personalized tests for drugs. Its solutions provide the R&D departments of Pharma and Research Institutes with the means to meet their most challenging research and innovation goals. This is done through a sophisticated, software-as-a-service, machine learning platform that comprehensively integrates multi-omics and clinical data, thus reducing the number of samples and additional validation experiments needed. Since 2013, InSyBio has worked with hundreds of academics, large and small companies, hospitals, and research centers, allowing them to succeed in their biomarker discovery tasks with an increase of at least 10% in predictive accuracy and a decrease of at least 80% in overall time and cost.